about
Tackling Unwanted Proteolysis in Plant Production Hosts Used for Molecular FarmingIxekizumab for the Treatment of Psoriasis: A Review of Phase III TrialsThe Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen ImmunotherapyHuman IgG4: a structural perspectiveAntibody-drug conjugates as novel anti-cancer chemotherapeuticsStability engineering of the human antibody repertoireSelective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal CancerImproving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesisProteolytic Processing of ErbB4 in Breast CancerKey factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentComparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc GlycoformsThe Structural Basis of Antibody-Antigen RecognitionA novel monoclonal antibody to CD40 prolongs islet allograft survivalResponse of a concentrated monoclonal antibody formulation to high shearDynamic fluctuations of protein-carbohydrate interactions promote protein aggregation.Progress towards recombinant anti-infective antibodies.Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in miceThe structure of dual-variable-domain immunoglobulin molecules alone and bound to antigenA new tool for monoclonal antibody analysis: application of IdeS proteolysis in IgG domain-specific characterization.Large-scale in vitro expansion of polyclonal human switched-memory B lymphocytes.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Mathematical modeling provides kinetic details of the human immune response to vaccination.Estimation of polyclonal IgG4 hybrids in normal human serum.The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation.A polar ring endows improved specificity to an antibody fragment.Monoclonal antibodies and toxins--a perspective on function and isotype.Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice.Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodiesStabilizing the CH2 Domain of an Antibody by Engineering in an Enhanced Aromatic SequonAcid-induced aggregation propensity of nivolumab is dependent on the Fc.Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress.Anti-coreceptor therapy drives selective T cell egress by suppressing inflammation-dependent chemotactic cues.Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse modelPhotoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor.Stability of IgG isotypes in serum.Fc-fusion proteins: new developments and future perspectives.Structural genomic alterations in primary mediastinal large B-cell lymphoma.Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV.
P2860
Q26750988-4EE90B10-734F-4F48-9387-405521B52561Q26766567-10879CD4-803A-4B4D-B4AE-710BC82C5520Q26771289-33BB7B26-22C4-475A-B90C-D9C5D9FAAB4AQ26779758-006798D4-81E2-4B4E-B20D-6723F273C478Q26800175-D199C3C1-557C-45F4-A454-E1F134C73526Q26859495-A636F2DE-4B21-4AF2-B223-0347B1EB0E53Q27306938-D5BFAA72-B5DD-40BC-B78B-15D4E91B171FQ27660092-1F8C61B7-CBE9-43B7-B4AC-0B6463DCC66DQ27670640-3DE2A763-6858-4359-8824-A04BCA61282EQ28082880-23849F85-8AFA-4226-BBF3-9040717AAC81Q28820826-A239FFF0-C196-40AF-A94C-2E8483FFB073Q28972262-C3ED304B-77DC-45B4-9C61-741322A51DF5Q30417821-20497451-F0FE-4001-8D1D-D77C94A8D68EQ30480156-B9BBE772-5A4F-402A-9F20-E0A1B662628AQ33520919-274A9C18-9851-46C1-8793-E6046CD07CC4Q33568256-1DC64951-0E78-4B26-B924-EB28C0B61AB6Q33707941-943EA94A-9E6C-4FFF-B00C-07181EDE3E99Q34212743-243FB5A6-5DA9-4605-A00B-E25B8517B7F1Q34223967-DFBD84CD-F3CA-418E-82F1-1F7C4AA374DDQ34532604-1C423198-9DC8-43AB-9FDA-B430F3864016Q34869927-F1A03114-9DD7-4752-816E-E7DEEBE47BC5Q34885695-4F8A6C8B-0271-4BDA-8B06-18CFCA11957FQ35089873-00491B2B-4726-4D0E-971E-5EC33FE26E5DQ35126618-6FCAEE50-4237-43D5-A63F-FC246CBA8301Q36059271-A9816ECB-F1ED-4C7F-9145-8F2BA5D1AE0BQ36099489-68FD9FC8-72FF-4F49-9C61-1BAC80CB9A6FQ36440069-EEF5AEB6-C6DE-4542-848C-ACB9E78DDD21Q36786293-64333EAD-83DE-4B37-AD3F-F22CD1552456Q36855617-DF0CB8B7-2244-4E85-BC25-D947BA94D25DQ37141601-EA6BC57E-93C9-4957-BC45-94E491FACD1CQ37318764-B8F81C7D-E6AC-4DEF-948E-22F230EE2F85Q37351576-27FF69DE-4F3D-465B-9994-8796C4C9E70CQ37376269-B68A1009-AF81-4C91-8CAA-962AC0338C9CQ37732381-5150C547-621C-430F-B8F2-3B91BE9EEE58Q37734089-9C75755A-1592-4018-A4E7-62D1FA649FEDQ38029985-B66D0D23-5CAE-4762-98F8-5BA140B2269AQ38267888-A6BAA2FE-25EA-418E-A813-523BC1B868C3Q38453769-DE68D40E-E0CD-43E6-BB93-EBB1AD329FA1Q38489049-9B7A2837-118E-4B67-B3BB-6C7E10C63E71Q38688524-905BBF9A-2DB9-4407-8BCD-997B2CA92354
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Isotype selection in antibody engineering.
@en
Isotype selection in antibody engineering.
@nl
type
label
Isotype selection in antibody engineering.
@en
Isotype selection in antibody engineering.
@nl
prefLabel
Isotype selection in antibody engineering.
@en
Isotype selection in antibody engineering.
@nl
P356
P1433
P1476
Isotype selection in antibody engineering.
@en
P2093
Jochen G Salfeld
P2888
P304
P356
10.1038/NBT1207-1369
P577
2007-12-01T00:00:00Z